Theravance

Pharma

After trial fail, Teravance is bought out by Zymeworks for $929M

Four months after Theravance Biopharma signaled it was up for sale, the Dublin-based company has agreed to be bought out by Zymeworks for $929 million

Kevin Dunleavy Jun 29, 2026 11:30am

Theravance's COPD med Yupelri flunks head-to-head study

Jan 5, 2024 10:14am

Biogen is reportedly homing in on a pick for its next CEO

Oct 7, 2022 2:07pm